Centre for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, Solna, Sweden.
Expert Rev Anti Infect Ther. 2011 Jan;9(1):33-47. doi: 10.1586/eri.10.157.
Rodent-borne pathogenic hantaviruses cause two severe and often lethal zoonotic diseases: hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome (HCPS) in the Americas. Currently, no US FDA-approved therapeutics or vaccines are available for HFRS/HCPS. Infections with hantaviruses are not lytic, and it is currently not known exactly why infections in humans cause disease. A better understanding of how hantaviruses interfere with normal cell functions and activation of innate and adaptive immune responses might provide clues to future development of specific treatment and/or vaccines against hantavirus infection. In this article, the current knowledge regarding immune responses observed in patients, hantavirus interference with cellular proteins and signaling pathways, and possible approaches in the development of therapeutics are discussed.
欧亚大陆的肾综合征出血热（HFRS）和美洲的汉坦病毒心肺综合征（HCPS）。目前，尚无获得美国食品和药物管理局（FDA）批准的 HFRS/HCPS 治疗药物或疫苗。汉坦病毒感染不是裂解性的，目前尚不清楚为什么人类感染会导致疾病。更好地了解汉坦病毒如何干扰正常细胞功能以及固有和适应性免疫反应的激活，可能为未来针对汉坦病毒感染开发特定治疗药物和/或疫苗提供线索。本文讨论了目前关于患者中观察到的免疫反应、汉坦病毒对细胞蛋白和信号通路的干扰以及治疗药物开发中可能的方法的知识。
